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Background: Either palliative distal gastrectomy or gastrojejunostomy are the initial treatment options for locally
advanced gastric cancer with outlet obstruction when curative-intent resection is not feasible. Since chemotherapy
is the mainstay for unresectable gastric cancer, the clinical value of palliative distal gastrectomy is controversial.
Methods: We retrospectively reviewed the clinical data of patients with gastric cancer with outlet obstruction treated
at our institution between January 2002 and December 2012. We compared the clinical outcomes of palliative distal
gastrectomy with those of gastrojejunostomy patients and the factors affecting overall survival were evaluated.
Results: Elective palliative distal gastrectomy and gastrojejunostomy were performed in 18 and 25 patients, respectively.
The median overall survival times in the gastrojejunostomy and palliative distal gastrectomy groups were statistically
equivalent at 8.8 and 8.3 months, respectively (P= 0.73), despite the more locally advanced tumors in the gastrojejunostomy
as compared with the palliative distal gastrectomy group. A multivariate Cox regression analysis showed absence of
postoperative chemotherapy and higher postoperative complication grade to be associated with worse clinical outcomes.
Conclusions: Palliative distal gastrectomy offers neither survival nor palliative benefit as compared to gastrojejunostomy.
Minimizing the morbidity of intervention for outlet obstruction, followed by chemotherapy, appears to be the optimal
initial strategy for incurable gastric cancer with outlet obstruction.
Keywords: Gastric cancer with outlet obstruction, Gastrojejunostomy, Palliative distal gastrectomyBackground
Gastric cancer with outlet obstruction (GCOO) is a locally
advanced malignancy characterized by tumor ingrowth.
GCOO is also associated with outward tumor growth and
invasion, as evidenced by 47% of GCOO showing direct
invasion of adjacent organs [1]. More importantly, GCOO
frequently metastasizes to lymph nodes (93%), the periton-
eum (34%), and the liver (15%) [1], suggesting a syste-
mically advanced tumor. Patients with GCOO had worse
clinical outcomes than those without outlet obstruction
even after curative resection [2].* Correspondence: okumura-tky@umin.ac.jp
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unless otherwise stated.Although chemotherapy is generally the mainstay for
treatment of advanced disease, the symptoms associated
with GCOO, such as nausea, vomiting, and poor nutri-
tional status due to impaired food intake, hamper admin-
istration of oral regimens. In fact, most clinical trials of
palliative chemotherapy for advanced/recurrent gastric
cancer exclude these patients [3-5] as chemotherapeutic
regimens commonly consist of the oral fluoropyrimidine
derivative S-1/capecitabine, alone or in combination
with other drugs. Therefore, the initial management
step for outlet obstruction should be urgent surgical or
endoscopic relief of obstructive symptoms, followed by
systemic chemotherapy.
When we select a surgical approach for a GCOO patient
and then identify a factor rendering the tumor incurable,al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the optimal approach? Resection reportedly confers a 3 to
5 month survival benefit over non-resection and 8 months
overall even in the palliative setting, such that palliative
gastrectomy, if feasible, was long considered to be the best
option for incurable GCOO [1,6,7]. However, this view
has changed in the last decade. Recently, median survival
times (MST) after palliative gastrectomy have gradually
been increasing and have now reached nearly 1 year ac-
cording to the literature [8-11]. This survival improvement
is likely attributable to the recent development of chemo-
therapy for unresectable advanced/recurrent gastric can-
cer providing MST of 1 year or longer [5,12,13]. It is
noteworthy that the presence of postoperative chemother-
apy is a powerful indicator of prolonged survival after
cytoreductive palliative gastrectomy [8-11].
However, according to the study results currently avail-
able, debate continues as to whether non-curative gastrec-
tomy followed by systemic chemotherapy or chemotherapy
without gastrectomy is most appropriate for incurable
GCOO. We evaluated clinical outcomes using our cohort
with incurable GCOO to determine the optimal procedure
for this disease entity in the present study.
Methods
Patient population
Between January 2002 and December 2012, a total of
1,531 patients with gastric cancer were treated at the
Department of Surgery, The University of Tokyo. Among
these 1,531 patients, 97 (6.3%) were diagnosed as having
GCOO, and we retrospectively reviewed their clinical re-
cords. GCOO is defined as an advanced gastric cancer
arising from the distal third of the stomach with symp-
toms including nausea, vomiting, or inability to consume
a regular diet. Even if patients did not suffer these symp-
toms, endoscopically-proven massive food residue in the
stomach or inability to pass the endoscope into the duode-
num is considered to represent GCOO. Five patients with
outlet obstruction due to progressive primary disease after
chemotherapy failure were excluded. The remaining 92
patients constituted the entire cohort with GCOO.
In our cohort, R0 and R1 resections were achieved in 22
and 6 patients, respectively. Among the remaining 64, 3
patients underwent emergency operations (1 gastrectomy
and 2 gastrojejunostomy (GJ)) for perforation or uncon-
trolled bleeding from a gastric cancer. Exploratory laparot-
omy/staging laparoscopy and feeding jejunostomy were
performed for 4 and 3 patients, respectively. Chemotherapy
was the initial treatment in 8 patients. Total gastrectomy
was performed in 3 patients with palliative intent. The
remaining 43 patients receiving GJ or palliative distal gas-
trectomy (PDG) were evaluated in this study (Figure 1).
Our protocol was approved by the ethics committee of the
faculty of medicine, the University of Tokyo.GJ and PDG were performed in 25 and 18 patients, re-
spectively. Postoperative complications were classified ac-
cording to the Clavien-Dindo system [14]. Complications
of grade 2 or higher were defined as postoperative mor-
bidity [15]. We also assessed oral intake employing the
gastric outlet obstruction scoring system (GOOSS), where
0 = no oral intake, 1 = liquids only, 2 = soft solids, and 3 =
low-residue or full diet [16]. ΔGOOSS was calculated by
subtracting preoperative GOOSS from postoperative
GOOSS. Performance status (PS) was assessed employing
the European Clinical Oncology Group (ECOG) scale.
Postoperative chemotherapy was performed after suffi-
cient postoperative recovery. S-1 combined with cisplatin
(CDDP) is the first choice for patients with a favorable
postoperative course and adequate renal function. Other-
wise, basically S-1, alone or combined with a taxane de-
rivative, was selected.
We conducted tumor staging according to the Union for
International Cancer Control TNM staging system for the
stomach [17]. We evaluated tumor histology according to
the Lauren classification [18]. Well and moderately differ-
entiated tubular adenocarcinoma, papillary adenocarcin-
oma, and solid type poorly differentiated adenocarcinoma
were classified as intestinal-type carcinomas; non-solid
type poorly differentiated adenocarcinoma, signet ring
cell carcinoma, and mucinous carcinoma were classified
as diffuse-type carcinomas. Other tumors were classi-
fied separately.Statistical analysis
Statistical analyses were carried out using JMP 10.0.2 (SAS
institute, Cary, NC, USA). The overall survival rates were
calculated from the operation date. Kaplan-Meier survival
curves were used to estimate the impact of each procedure
in our series, and the log-rank test was employed for
comparisons.
Differences in patient characteristics (sex, histology,
direct invasion of adjacent organs (T4b), liver metasta-
sis (H), peritoneal metastasis (P), stage, and presence/
absence of postoperative morbidity, and chemotherapy)
as categorical variables were compared between the GJ
and PDG groups by the χ2 test. The Wilcoxon test was
conducted for continuous variables including age,
ECOG PS, preoperative GOOSS, operative time, intra-
operative blood loss, and ΔGOOSS. A Cox proportional-
hazards analysis was performed to identify independent
prognostic factors among the variables (sex, age, ope-
rative procedure (GJ or PDG), ECOG PS, histology (in-
testinal or diffuse type adenocarcinoma), preoperative
GOOSS, presence/absence of postoperative chemother-
apy, postoperative complications, T4b, H, and P) for
overall survival. P values less than 0.05 were considered
significant.
Figure 1 CONSORT diagram for this study. We retrospectively reviewed 25 gastrojejunostomy cases and 18 palliative distal gastrectomy cases.
DG, Distal gastrectomy; GCOO, Gastric cancer with outlet obstruction; GJ, Gastrojejunostomy; TG, Total gastrectomy.
Table 1 Characteristics of 43 patients undergoing
gastrojejunostomy or palliative distal gastrectomy
Gastrojejunostomy Gastrectomy P value
(n = 25) (n = 18)
Sex
Male:female 17:8 10:8 0.40
Age
Median (range) 70 (52–82) 74 (44–88) 0.42
Histology





Peritoneal metastasis 19 13 0.78





IIIC:IV 4:21 1:17 0.29
ECOG PS
0:1:2:3 13:10:2:0 11:3:1:3 0.87
Preoperative GOOSS
0:1:2:3 15:8:1:1 6:5:1:6 0.02
Number of patients with
preoperative TPN
16 5 0.02
ECOG, European Clinical Oncology Group; GOOSS, Gastric outlet obstruction
scoring system; TPN, Total parenteral nutrition.
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Sixty of the 92 patients (65%) with GCOO had Stage IV
disease, and the incidences of T4b, H, and P were 40%,
15%, and 40%, respectively. Gastrectomy was performed
in 49 cases including 22 R0, 6 R1, and 21 R2 resections.
The clinical characteristics of the 43 patients undergoing
elective surgery with GJ or PDG are summarized in
Table 1. Sex, age, stage, and ECOG PS showed no statisti-
cally significant differences between the GJ and PDG
groups. Preoperative GOOSS was significantly worse (P =
0.02) and the majority required total parenteral nutrition
(64% vs. 28%, P = 0.02) in the GJ group. Intestinal type was
the dominant histology in the GJ group but not in the
PDG group (64% vs. 33%, P = 0.05). Although the rates of
H, P, and distant lymph node metastasis were equivalent
in these two groups, 88% of patients with GJ had T4b tu-
mors while only 11% of the PDG group had T4b tumors
(P <0.0001).
All GJ procedures were of the stomach-partitioning type.
All procedures were performed by an open approach.
Operative times did not differ significantly (165 vs.
189 min, P = 0.08), while intraoperative blood loss was sig-
nificantly lower (86 mL vs. 215 mL, P = 0.02) in the GJ
group (Table 2). ΔGOOSS and number of patients given
postoperative chemotherapy did not differ significantly.
Eight patients (32%) in the GJ group had complications, in-
cluding two with anastomotic stricture, two with anorexia,
three with catheter infection, and one with another compli-
cation. Meanwhile, two patients (11%) in the PDG group
had complications, including anorexia and urinary tract
Table 2 Early outcomes and chemotherapy after
gastrojejunostomy and palliative gastrectomy
Gastrojejunostomy Gastrectomy P value
(n = 25) (n = 18)
Operative time (min) 165 (102–365) 189 (94–364) 0.08
Intraoperative blood loss
(mL)
86 (0–950) 215 (42–790) 0.02
ΔGOOSS
Median (range) 2 (0–3) 1 (−2–3) 0.13
Morbidity 8 2 0.10
Anastomotic stricture 2 0
Anastomotic leakage 0 0
Anorexia 2 1








S-1 + CDDP 13 6
S-1 + Taxane(DTX/PTX) 0 2
Other 0 2
CDDP, Cisplatin; DTX, Docetaxel; GOOSS, Gastric outlet obstruction scoring
system; PTX, Paclitaxel.
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tween the two groups (P = 0.10).
Chemotherapeutic regimens are summarized in Table 2.
Postoperative chemotherapy was given to 19 (76%) of the
GJ and 15 (83%) of the PDG group patients. MST were 8.8
and 8.3 months in the GJ and PDG groups, respectively,
and were not significantly different (P = 0.73, Figure 2a).
Univariate analysis showed survival to be significantly re-
lated to ECOG PS, presence of postoperative chemother-
apy, and absence of postoperative complications (Table 3).
A multivariate Cox regression analysis showed absence of
postoperative chemotherapy and presence of postoperative
complications to be independently associated with poor
clinical outcomes. Patients receiving postoperative chemo-
therapy had significantly better survival than those who did
not (MST 11.2 vs. 4.7 months, P <0.0001, Figure 2b). MST
of patients with and without postoperative complications
were 4.9 and 11.2 months, respectively (P <0.0001,
Figure 2c).Discussion
In our study, GCOO showed high incidences of T4b, H,
and P. Our results are mostly consistent with those of a
previous report [1]. Therefore, GCOO is characterized
by a high probability of Stage IV disease and has a poorprognosis. Chemotherapy is clearly the mainstay in treat-
ing this population.
In our series, surgical procedures were selected by sur-
geons according to the individual needs of their patients.
During this period, we preferentially selected gastrectomy,
if feasible, even when factors making a tumor incurable
were present. This was based mainly on obtaining a pos-
sible survival benefit with R2 gastrectomy over GJ, as
demonstrated in previous studies [6,8]. In fact, there were
only three tumors (14%) in the GJ group without adjacent
organ infiltration, while 89% of tumors in the PDG group
had this feature.
R2 gastrectomy is known to be associated with high
morbidity and mortality rates as compared with R1 re-
section or GJ [19]. Although GJ is assumed to be a less
invasive and lower morbidity alternative for GCOO, our
results do not support this assumption. In our study, GJ
had a shorter operative time and significantly less intra-
operative blood loss, though postoperative morbidity
was not better, instead actually being worse, than with
PDG. There were three procedure conversions from
PDG to GJ after extensive peritumoral area manipula-
tion. This challenging situation resulted in longer opera-
tive times, larger amounts of blood loss, and more
postoperative complications. Intraoperative conversions
and other challenges should be avoided whenever pos-
sible and PDG cannot be recommended, at least for T4b
disease, according to our present results.
Gastrectomy was long considered to basically be the
best option, even for stage IV patients, in some institutes
[6,7]. Since recent advances in chemotherapy have pro-
duced high response rates and prolonged the survival of
patients with gastric cancer [5,12,13], chemotherapy rather
than cytoreductive gastrectomy has come to play an es-
sential role in the treatment of incurable gastric cancer
[8-11]. Epirubicin, oxaliplatin, and capecitabine combin-
ation therapy achieved a higher response rate (47.9%) and
longer overall survival (MST, 11.2 months) than other
triplet combination therapies with cisplatin or fluorouracil
in the REAL-2 trial [20]. In Japan, doublet administration
with S-1 plus cisplatin became the standard first-line regi-
men after the SPIRITS trial, demonstrating a response rate
of 54% and a MST of 13 months [12]. These regimens
contain the oral fluoropyrimidine derivative S-1/capecita-
bine, with the intake being uniquely impeded by GCOO,
such that the most promising chemotherapies are not an
option for patients whose initial status is GCOO. There-
fore, initiation of chemotherapy, rather than an operative
procedure, was associated with better survival in patients
with Stage IV GCOO, in this retrospective study.
According to the multivariate Cox regression analysis,
operative procedure was not a prognostic factor in patients
with GCOO. Meanwhile, absence of postoperative chemo-
therapy and presence of postoperative complications were
Figure 2 Survival curve of 43 patients with incurable gastric cancer with outlet obstruction. (a) Overall survivals after gastrojejunostomy
and palliative distal gastrectomy. Overall survival did not differ between the gastrojejunostomy and palliative distal gastrectomy groups (P = 0.73).
(b) Overall survivals of patients with and without postoperative chemotherapy. Patients with postoperative chemotherapy had significantly better
survival than those without (P <0.0001). (c) Overall survivals of patients with and without postoperative complications. Patients who had
postoperative complications had significantly worse survival than those who did not (P <0.0001).
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Table 3 Factors predicting overall survival
Variables Univariate Multivariate
HR CI (95%) P value HR CI (95%) P value
Sex 1.73 0.79–3.59 0.16
Age 1.41 0.69–2.96 0.35
Operative procedure 1.13 0.56–2.28 0.73
ECOG PS 3.01 1.08–7.22 0.04 1.78 0.54–5.40 0.33
Histology 1.12 0.55–2.30 0.76
Preoperative GOOSS 1.22 0.51–2.62 0.63
Postoperative chemotherapy 0.20 0.09–0.48 0.0007 0.16 0.06–0.49 0.0016
Postoperative complication(s) 3.68 1.50–8.62 0.0054 5.88 2.24–15.35 0.0005
Liver metastasis 2.43 0.95–5.49 0.06
Peritoneal metastasis 1.04 0.51–2.13 0.92
Direct invasion into neighboring organ(s) 1.22 0.60–2.46 0.58
CI, Confidence interval; ECOG, European Clinical Oncology Group; GOOSS, Gastric outlet obstruction scoring system; HR, Hazard ratio.
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complications delayed recovery and disrupted subsequent
chemotherapy, in general. In fact, 3 of the 11 patients (27%)
with postoperative morbidity received no chemotherapy.
Therefore, intervention without complications is essential
in the treatment of unresectable GCOO.
Theoretically, endoscopic stenting is the most minimally
invasive approach for outlet obstruction currently avail-
able. Self-expanding stents reportedly achieve earlier im-
provement of oral intake and a lower morbidity rate than
surgical interventions [21-24]. Recent reports have recom-
mended endoscopic stenting for patients with life expect-
ancies shorter than 2 months, while GJ is preferable for
those with good PS and/or longer estimated survival ac-
cording to their patency duration [23-25]. Endoscopic
stenting has been shown, by two randomized controlled
trials comparing it with GJ, to offer better short term out-
comes [26,27]. Although the populations consisted mainly
of patients with pancreatic cancer in these prior studies,
endoscopic stenting might be a minimally invasive option
for patients with GCOO as well.
Ohashi et al. reported the efficacy of GJ as the initial
therapy for incurable GCOO [28]. The MST of patients
with incurable GCOO after GJ followed by S-1-based
chemotherapy was reported to be 354 days [27]. This
strategy seems to be feasible and is supported by case re-
ports describing successful treatments [29-32]. In these
cases, gastrectomy with curative intent was achieved after
marked tumor shrinkage in response to chemotherapy.
Since endoscopic stenting is associated with a lower com-
plication rate and earlier initiation of chemotherapy, it
might be worthwhile to evaluate whether or not the bridge
to surgery concept, a promising treatment strategy for ob-
structive colorectal cancer, is also feasible for GCOO.
The major limitations of this study are its small popu-
lation size, retrospective nature, and it having beenconducted in a single institution. Furthermore, no defin-
ite protocol to select either procedure yielded clear dif-
ferences in patient characteristics between the two
groups, especially regarding depth of the primary tumor,
as was demonstrated by one retrospective study advocat-
ing palliative gastrectomy over GJ and endoscopic stent-
ing for GCOO [33]. A prospective study excluding T4b
tumors is warranted before any definite conclusions can
be drawn.
Conclusions
In conclusion, PDG offers neither survival nor palliative
benefit as compared to GJ. Therefore, surgical removal
should not necessarily be recommended for patients
with this pathology. Intervention without complications
and induction chemotherapy constitute an ideal initial
approach for patients with unresectable GCOO. Chemo-
therapy, rather than cytoreductive gastrectomy, plays an
essential role in improving the outcomes of this patient
population.
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